argenx Reports Strong Financial Performance and Pipeline Progress in 2024

In 2024, argenx SE (Euronext & Nasdaq: ARGX), a global immunology company, reported strong financial results and provided a fourth quarter business update, highlighting significant growth and progress in its pipeline. The company's focus on innovation, investment in its pipeline, and strategic execution have positioned it for expected profitability in 2025.

Financial Performance:

argenx generated $737 million in fourth quarter and $2.2 billion in full-year global product net sales in 2024. This represents a substantial increase compared to the $573 million in third quarter and $1.5 billion in full-year 2023 sales. The company's revenue growth can be attributed to the expansion of its global patient reach with VYVGART, surpassing 10,000 patients across three indications by the end of 2024. argenx's strong financial performance is also driven by the successful launch of VYVGART Hytrulo in CIDP, which has received positive feedback from patients and physicians.



Pipeline Progress:

argenx continues to demonstrate breadth and depth within its immunology pipeline, advancing multiple first-in-class product candidates with potential across high-need indications. The company is expected to have 10 Phase 3 and 10 Phase 2 studies ongoing in 2025, positioning it for the next wave of growth. By 2030, argenx aims to advance five pipeline candidates into Phase 3 development as part of its Vision 2030 strategic priorities.

Some of the pipeline candidates expected to advance into Phase 3 development by 2030 include:

1. Efgartigimod: argenx is solidifying its leadership in FcRn biology with efgartigimod, which is currently in development in 15 indications. The company is expected to advance registrational studies of efgartigimod in thyroid eye disease (TED) and primary Sjögren's disease (SjD), among other indications.
2. Empasiprubart: argenx is advancing its first-in-class C2 inhibitor, empasiprubart, which is being evaluated in multifocal motor neuropathy (MMN), delayed graft function (DGF), dermatomyositis (DM), and CIDP. The company is expected to begin registrational studies of empasiprubart in MMN and other indications.
3. ARGX-119: argenx is evaluating ARGX-119, a muscle-specific kinase (MuSK) agonist, in both congenital myasthenic syndrome (CMS) and amyotrophic lateral sclerosis (ALS). The company is expected to advance registrational studies of ARGX-119 in these indications.

argenx's strong financial performance in 2024, driven by the expansion of its global patient reach and the successful launch of VYVGART Hytrulo in CIDP, sets the stage for expected profitability in 2025. The company's commitment to innovation, investment in its pipeline, and strategic execution have positioned it for continued success in the coming years. With an expansive pipeline and a focus on treating 50,000 patients globally with its medicines, securing 10 labeled indications across all approved medicines, and advancing five pipeline candidates into Phase 3 development by 2030, argenx is well-positioned to continue its growth and make a significant impact in the immunology space.